Trials / Completed
CompletedNCT02923726
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP (APPRAISE ATP)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2,692 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Arm 1 (ATP+Shock) | Subjects will be randomized and device programmed to the respective arm. |
| DEVICE | Arm 2 (shock only) | Subjects will be randomized and device programmed to the respective arm. |
Timeline
- Start date
- 2016-09-30
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
- First posted
- 2016-10-05
- Last updated
- 2024-10-22
- Results posted
- 2024-10-22
Locations
134 sites across 8 countries: United States, Austria, Canada, Italy, Japan, South Korea, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02923726. Inclusion in this directory is not an endorsement.